AU2016362830B2 - Cytarabine conjugates for cancer therapy - Google Patents

Cytarabine conjugates for cancer therapy Download PDF

Info

Publication number
AU2016362830B2
AU2016362830B2 AU2016362830A AU2016362830A AU2016362830B2 AU 2016362830 B2 AU2016362830 B2 AU 2016362830B2 AU 2016362830 A AU2016362830 A AU 2016362830A AU 2016362830 A AU2016362830 A AU 2016362830A AU 2016362830 B2 AU2016362830 B2 AU 2016362830B2
Authority
AU
Australia
Prior art keywords
acid
astarabine
subject
cytarabine
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016362830A
Other languages
English (en)
Other versions
AU2016362830A1 (en
Inventor
Ruth BEN YAKAR
Stela Gengrinovitch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosight Ltd
Original Assignee
Biosight Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosight Ltd filed Critical Biosight Ltd
Publication of AU2016362830A1 publication Critical patent/AU2016362830A1/en
Priority to AU2022204373A priority Critical patent/AU2022204373B2/en
Application granted granted Critical
Publication of AU2016362830B2 publication Critical patent/AU2016362830B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
AU2016362830A 2015-12-03 2016-01-25 Cytarabine conjugates for cancer therapy Ceased AU2016362830B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022204373A AU2022204373B2 (en) 2015-12-03 2022-06-22 Cytarabine conjugates for cancer therapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562262428P 2015-12-03 2015-12-03
US62/262,428 2015-12-03
PCT/IL2016/050077 WO2017093993A1 (en) 2015-12-03 2016-01-25 Cytarabine conjugates for cancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022204373A Division AU2022204373B2 (en) 2015-12-03 2022-06-22 Cytarabine conjugates for cancer therapy

Publications (2)

Publication Number Publication Date
AU2016362830A1 AU2016362830A1 (en) 2018-07-12
AU2016362830B2 true AU2016362830B2 (en) 2022-07-14

Family

ID=58796462

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016362830A Ceased AU2016362830B2 (en) 2015-12-03 2016-01-25 Cytarabine conjugates for cancer therapy
AU2022204373A Ceased AU2022204373B2 (en) 2015-12-03 2022-06-22 Cytarabine conjugates for cancer therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022204373A Ceased AU2022204373B2 (en) 2015-12-03 2022-06-22 Cytarabine conjugates for cancer therapy

Country Status (10)

Country Link
US (1) US11058701B2 (enExample)
EP (1) EP3383407B1 (enExample)
JP (3) JP7149183B2 (enExample)
CN (1) CN108289905A (enExample)
AU (2) AU2016362830B2 (enExample)
BR (1) BR112018011177A2 (enExample)
CA (1) CA3007058C (enExample)
IL (2) IL259631B (enExample)
RU (1) RU2708672C1 (enExample)
WO (1) WO2017093993A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2747528C2 (ru) 2015-12-03 2021-05-06 Биосайт Лтд. Соли конъюгатов для лечения рака
US12071450B2 (en) 2015-12-03 2024-08-27 Biosight Ltd. Salts of conjugates for cancer therapy
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
JP7305613B2 (ja) * 2017-07-09 2023-07-10 バイオサイト リミテッド 併用がん療法
CN110590862A (zh) * 2019-11-01 2019-12-20 南京师范大学 阿糖胞苷4-n位氨基酸衍生物及其制备方法与应用
IL295323A (en) * 2020-02-04 2022-10-01 Biosight Ltd Pharmaceutical compositions containing especitarabin and their use
US20230158055A1 (en) * 2020-04-23 2023-05-25 Biosight Ltd. Methods and regimens for the treatment of hematological cancer
WO2022059013A1 (en) * 2020-09-21 2022-03-24 Biosight Ltd. Crystalline form of aspacytarabine
CN112409431B (zh) * 2020-12-07 2023-04-21 武汉伯瑞恒医药科技有限公司 阿糖胞苷结构类似物及其制备方法和用途
KR20240113533A (ko) * 2021-11-21 2024-07-22 바이오사이트 리미티드 암 치료를 위한 시타라빈-아미노산 기반 전구약물
WO2023175622A1 (en) * 2022-03-17 2023-09-21 Biosight Ltd. Crystalline forms of aspacytarabine
WO2023228177A1 (en) * 2022-05-22 2023-11-30 Biosight Ltd. Compositions comprising aspacytarabine and additional compounds, and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110275590A1 (en) * 2004-02-02 2011-11-10 BioSight Ltd., Conjugates for cancer therapy and diagnosis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2949451A (en) 1959-04-21 1960-08-16 Hoffmann La Roche Preparation of thymidine and deoxyfluorouridine, and intermediates therefor
US3041335A (en) 1959-04-21 1962-06-26 Hoffmann La Roche Mercury salts of nitrogen heterocyclics and preparation thereof
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4296105A (en) 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
US4348522A (en) 1980-01-23 1982-09-07 Starks Associates, Inc. N-(phosphonacetyl)-L-aspartic acid salts with piperazine, cyclohexylamine and calcium
EP0329184A3 (en) 1988-02-19 1990-05-23 Neorx Corporation Antimers and antimeric conjugation
US6344213B1 (en) 1996-03-29 2002-02-05 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
RU2085557C1 (ru) 1991-09-30 1997-07-27 Санкио Компани Лимитед Производные нуклеозидов пиримидина или их фармацевтически приемлемые соли и способ их получения
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2180348A1 (en) * 1994-01-11 1995-07-13 Robert Plourde, Jr. Hepatocyte-targeted drug conjugates
EP1880737A1 (fr) 1994-08-19 2008-01-23 La Region Wallonne Composés, composition pharmaceutique et dispositif de diagnostic les comprenant et leur utilisation
JPH0859688A (ja) 1994-08-25 1996-03-05 Mitsui Toatsu Chem Inc ５’−チオノエステル置換トリフルオロチミジン誘導体およびそれを有効成分とする制癌剤
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6258774B1 (en) 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
AU773420B2 (en) 1998-12-11 2004-05-27 Medarex, Inc. Prodrug compounds and process for preparation thereof
WO2004041837A1 (en) 2002-10-31 2004-05-21 Metabasis Therapeutics, Inc. Novel cytarabine monophosphate prodrugs
WO2008072963A1 (en) 2006-12-13 2008-06-19 Givaudan Nederland Services B.V. Flavour modulating derivative of a carboxylic acid and a purine, pyrimidine, nucleoside or nucleotide
CN101812105A (zh) 2009-02-25 2010-08-25 沈阳药科大学 阿糖胞苷5’-o-氨基酸酯和其盐类及其制备方法
JP5873656B2 (ja) * 2011-06-13 2016-03-01 株式会社Ihi 金属サレン錯体化合物、局所麻酔薬剤及び抗悪性腫瘍薬剤
WO2013058294A1 (ja) 2011-10-18 2013-04-25 味の素株式会社 膵臓癌及び／又は胆道癌治療薬
EP2934549A4 (en) * 2012-12-18 2016-06-01 Godavari Biorefineries Ltd MEANS FOR ELIMINATING TUMORINITIATING CELLS
WO2015178265A1 (ja) 2014-05-23 2015-11-26 日本化薬株式会社 新規なグルタミン酸誘導体およびその用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110275590A1 (en) * 2004-02-02 2011-11-10 BioSight Ltd., Conjugates for cancer therapy and diagnosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BHUPENDER S C. et al., "Development of cytarabine prodrugs and delivery systems for leukemia treatment", EXPERT OPINION ON DRUG DELIVERY, GB, (2010-12-01), vol. 7, no. 12, , pages 1399 - 1414 *
RENIS, H. E ., "Antiviral Activity of Cytarabine in Herpesvirus-Infected Rats.", Antimicrobial agents and chemotherapy, vol. 4, no. 4, (1973), pages 439 - 444 *

Also Published As

Publication number Publication date
CN108289905A (zh) 2018-07-17
AU2022204373A1 (en) 2022-07-28
JP7417658B2 (ja) 2024-01-18
CA3007058C (en) 2023-10-17
JP2018535989A (ja) 2018-12-06
IL287644A (en) 2021-12-01
JP7149183B2 (ja) 2022-10-06
EP3383407A1 (en) 2018-10-10
RU2708672C1 (ru) 2019-12-11
WO2017093993A1 (en) 2017-06-08
US20180369265A1 (en) 2018-12-27
AU2016362830A1 (en) 2018-07-12
CA3007058A1 (en) 2017-06-08
IL259631A (en) 2018-07-31
US11058701B2 (en) 2021-07-13
IL259631B (en) 2021-10-31
JP2022097619A (ja) 2022-06-30
EP3383407A4 (en) 2019-07-17
JP2020183419A (ja) 2020-11-12
AU2022204373B2 (en) 2024-01-25
EP3383407B1 (en) 2023-12-06
BR112018011177A2 (pt) 2018-11-21

Similar Documents

Publication Publication Date Title
AU2022204373B2 (en) Cytarabine conjugates for cancer therapy
US6232298B1 (en) Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
CN110869029A (zh) 组合癌症治疗
JP4408450B2 (ja) 全身性炎症および炎症性肝炎の処置のためのピリミジンヌクレオチド前駆体
EP0679160B1 (en) Pyrimidine nucleotide precursors for treatment of inflammatory hepatitis
US12064445B2 (en) Cytarabine conjugates for cancer therapy
US6306901B1 (en) Agent for prophylaxis and therapy of diseases
US20150290232A1 (en) Drug composition for treating tumors and application thereof
HK40025426A (en) Combination cancer therapy
AU2005232281A1 (en) Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
HK1004484B (en) Pyrimidine nucleotide precursors for treatment of inflammatory hepatitis
AU5262499A (en) Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
HK1067068A (en) Pyrimidine nucleotide precursors for treatment of inflammatory hepatitis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired